Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | FPR3 | P25089 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28923421 | 0.83 | USP30 (0.56) | USP30LMNATHRBFPR3FPR2 | |
| SCHEMBL25192922 | 0.81 | USP30 (0.56) | USP30LMNATHRBFPR3FPR2 | |
| SCHEMBL28923235 | 0.80 | LMNA (0.45) | USP30LMNATHRBPOLBMAPT | |
| SCHEMBL27261581 | 0.80 | USP30 (0.59) | USP30FPR3FPR2 | |
| SCHEMBL28579659 | 0.79 | USP30 (0.52) | USP30LMNATHRBFPR3FPR2 | |
| SCHEMBL29779090 | 0.78 | USP30 (0.70) | USP30FPR3FPR2PARP1 | |
| SCHEMBL18124204 | 0.78 | USP30 (0.70) | USP30FPR3FPR2PARP1 | |
| SCHEMBL23019685 | 0.78 | USP30 (0.70) | USP30FPR3FPR2PARP1 | |
| SCHEMBL23533928 | 0.77 | USP30 (0.54) | USP30LMNATHRBFPR3FPR2 | |
| SCHEMBL3963418 | 0.76 | POLB (0.58) | USP30LMNATHRBPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | USP30 3026/4885LMNA 324/4885THRB 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.